EURIPID is a voluntary, non-profit collaboration of the European pricing and reimbursement authorities for the mutual sharing of information regarding pharmaceutical pricing policies and prices of medicinal products. Its main objective is to make pricing procedures and prices of pharmaceuticals more transparent in Europe. In order to do so, the EURIPID Collaboration set up and maintains a technical tool, the EURIPID database. The EURIPID database is a comprehensive, continuously maintained, easy-to-use online database of prices of reimbursed pharmaceuticals. The database is a resource tool for members of the EURIPID Collaboration and exclusively accessiblee for the national competent authorities of its participating countries and the services of the European Commission.

The EURIPID Collaboration consists of (1) founding members, (2) partners, (3) associated partners and (4) the European Commission (EC). Regarding its governance structure, the EURIPID Collaboration has a Board of Participants and an Executive Committee. The Board of Participants includes one delegate per country and a representative of the EC. The Executive Committee has six members: the delegates of the two founders, three delegates of the Board of Participants and one representative of the EC.

The EURIPID Collaboration is currently funded by an annual contribution fee of the participants and – for defined tasks (e.g. the public website) and deliverables – two grants of the European Commission awarded in 2019 and 2023.

The COVID-19 pandemic has shown that effective assessment and response requires diverse data from various disciplines. Evaluating the true impact of the outbreak requires data and statistical analysis that are not always readily available. The EU-funded PERISCOPE project aims to conduct in-depth multidisciplinary research to evaluate and better inform Europe’s response to the pandemic. It does so by assessing the outbreak’s impact while taking policy measures as well as epidemiological, health, socioeconomic impacts into account. The main goal of the project is to uncover the real impact of the pandemic by providing a wealth of data and statistical information, promoting evidence-based policymaking while informing effective outbreak response.

The mission of HEPA Europe is to provide a forum for the advancement of health-enhancing physical activity (HEPA) research, policy and practice for better health and well-being across the WHO European Region. HEPA Europe membership is open to organizations and institutions active at the regional, national or subnational level, who are willing to contribute to the goals and objectives of the network.

The SYNCHROS-project started Jan. 1st, 2019 and ends June 30th, 2022. The work towards the goal of Coordination and Support for “Synchronising Cohorts and Population Surveys in Europe and worldwide” is structured by 8 work packages and the following three phases.

The RECODID project will develop an equitable, accessible, and sustainable model for the storage, curation, and analyses of clinical-epidemiological and high-dimensional sample data collected by infectious disease cohorts in low-and-middle-income countries (LMIC).

HBM4EU is coordinating and advancing human biomonitoring in Europe and so provide better evidence of the actual exposure of citizens to chemicals. In addition, we provide a robust interpretation of human biomonitoring data and the possible impact of chemical exposure on human health, using the most up to date scientific tools.

HBM4EU partners effectively communicates results to policy makers, ensuring their exploitation in the design of new chemicals policies and the evaluation of existing measures.

This initiative contributes directly to the improvement of health and well-being for all citizens, by investigating how exposure to chemicals affects the health of different vulnerable groups, such as children and pregnant women, as well as of highly exposed groups like workers.

Data used and produced under HBM4EU will be made accessible via IPCHEM – the Information Platform for Chemical Monitoring. IPCHEM is the European Commission’s reference access point for searching, accessing and retrieving chemical occurrence data collected and managed in Europe. 

The overall objective of this 5-year project is to build a multinational, adaptive European COVID-19 and emerging infectious diseases trial network, based on existing initiatives, experience and expertise, allowing European expansion of DisCoVeRy and the establishment of a COVID-19 adaptive platform trial.

ORCHESTRA is a three-year international research project aimed at tackling the coronavirus pandemic, led by the University of Verona and involving 26 partners (extending to a wider network of 37 partners) from 15 countries: Argentina, Belgium, Brazil, Congo, France, Gabon, Germany, India, Italy, Luxemburg, Netherlands, Romania, Slovakia, Spain, Venezuela.

The project is funded by the European Union’s Horizon 2020 research and innovation programme under the ERAvsCORONA Action Plan which was developed jointly by Commission services and national authorities.

Objectives

• to develop evidence-based recommendations for effective prevention, protection and optimized treatment of COVID-19 patients (including long-term consequences) with a special focus on ‘at risk’ population, including healthcare workers and fragile individuals
• to assess impact of environmental factors, socio-economic determinants, lifestyle and confinement measures on the spread of COVID-19
• to provide knowledge on the efficacy of vaccines against SARS-CoV-2
• to provide a model for responsiveness for future pandemic outbreaks.

The overall goal of RECOVER is to understand the COVID-19 pandemic through clinical research in order to transform patient care and public health responses.